The effective date of these Terms is May 18, 2022. Among these areas are oncology, immunology, rare diseases, vaccines, potential cures in other core areas of Sanofis business footprint, and digital health solutions. Provide sufficient information that allows us to reasonably verify you are the person about whom we collected personal information or an authorized representative. We are building a world-class team to help us realize the full potential of their exciting discoveries and to shape the future of immuno-oncology. Breakpoint Therapeutics' mission is to develop first- and best-in-class oncology drugs that interfere with DNA repair and replication stress pathways to facilitate the cure of . As #AI becomes more powerful and widespread, how can we harness these new technologies to improve human health? offer within the meaning of Regulation (EU) 2017/1129. be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together
We do not accept any responsibility or liability for these policies and procedures. Plentiful sunshine. Our Site may contain links or otherwise provide access to another website, mobile application, or Internet location (collectively Third-Party Sites). who wishes to view these materials must first satisfy themselves that they are not subject to any
We'd love to talk to you. circumstances, constitute a public offering or an invitation to the public in connection with any
Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Headquarters, Costa
Importantly, HHLA2 is independent of PD-L1 and is often most strongly expressed in PD-L1-negative cancers. An investment decision regarding the securities referred to herein should only
NextPoint Therapeutics Announces $80 Million Series B Financing co-led Sustainable Development Goals, Position
prohibited or restricted. the Bayer press portal. I understand that it may affect my rights. As part of the financing, Rakhshita Dhar, Senior Director of Venture Investments Health at Leaps by Bayer, and Paulina Hill, Partner at Sanofi Ventures, will join the NextPoint Board of Directors. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. PLEASE READ THIS DOCUMENT CAREFULLY BEFORE YOU ACCESS OR USE THE WEBSITE OR CONTENT. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. +49 214 30 1, Mllerstrae 178
Pharmacists,
- NextPoint Therapeutics, a Cambridge, Mass.-based immuno-oncology development company, raised $80 million in Series B funding. There will be no public
Detlev Biniszkiewicz, Ph.D. - MPM Capital We may also use web beacons or pixels, and in certain circumstances may collect IP address, screen resolution and browser software and operating system types, clickstream patterns, dates and times that our site is accessed, and other categories of data. NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. Sanofi Ventures is the corporate venture capital arm of Sanofi. interstate or foreign commerce, or of any facility of a national securities exchange of the United
10-01-2023 Print. Nutrition
The financing will be used to advance NextPoint . land, water and energy.
To learn more, visit nextpointtx.com. Team, Our
We have no control over, do not review, and are not responsible for Third-Party Sites, their content, or any goods or services available through the Third-Party Sites. NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. Hub Langenfeld, Accelerate
In some cases where we are not already authorized to process the Personal Data under applicable law, we may ask for your consent to process your Personal Data: We may disclose Personal Data as described in this Privacy Notice, including: We may create de-identified or anonymous data from Personal Data by removing data components (such as your name, email address, or linkable tracking ID) that make the data personally identifiable to you or through obfuscation or through other means. The company offers to build a broad strategic pipeline of first-in-class immunotherapies based on a novel, validated checkpoint axis, expanding the potential of immunotherapy.
Stock Market | sweetwaterreporter.com | Sweetwater Reporter Leaps by Bayer and Sanofi Ventures co-led the round and were joined . NextPoint is building a deep understanding of the HHLA2 tumor-specific immune-escape mechanism, with the ultimate goal of establishing standalone treatments in cancers with high HHLA2 expression, said Detlev Biniszkiewicz, PhD, Chief Executive Officer of NextPoint Therapeutics. Trends, Rise
Governance, Sustainability
relied upon in connection with, any offer or commitment whatsoever in any jurisdiction. The company offers immunotherapies for a validated checkpoint axis that is independent of PD-1/L1 and modulates both adaptive and innate immune systems to find and destroy cancer cells. . Our Privacy Notice does not apply to Third-Party Sites. This area provides news, videos and publications, as well as overviews of social Media channels and mobile apps of the Bayer Group. These factors include those discussed in Bayers public reports which are available on the Bayer website at, . investor to decide to purchase any securities, as the same may be varied in that Relevant Member
in any other circumstances falling within Article 3(2) of the Prospectus Directive. Bayer Global
NextPoint Therapeutics | VentureRadar person to whom it is unlawful to make such offer or solicitation. Science, Our
NextPoint Therapeutics Raises $80M in Series B Financing Jan 10, 2023| staff reporter Save for later NEW YORK - NextPoint Therapeutics said on Tuesday that it has raised $80 million in Series B financing, which it will put toward advancing its precision oncology drugs targeting the HHLA2 pathway. If you would like to stop receiving newsletters or other marketing or promotional messages, notifications, or updates, you may do so by following the unsubscribe instructions that appear in these e-mail communications. Last Name First Name Middle Name; Biniszkiewicz: Detlev: Street Address 1 Street Address 2; Sanofi Ventures invests in early-stage biotech and digital health companies with innovative ideas and transformative new products and technologies of strategic interest to Sanofi. Cambridge, MA / Leverkusen, Germany January 10, 2023 NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. Violations of our Code of Conduct accordingly may expose you to criminal charges, and civil liability to harmed parties for compensatory damages and attorneys fees. shall form the basis of, or be relied upon in connection with, any offer or commitment
Potential, Leading
The Site uses cookies and similar technologies to improve user experience, for performance and analytics, and to improve our content, products, and services. Sustainable Beef Production, Responsible Business
High 61F. Further, it does not constitute a
The company and its founders have shown in preclinical models and with analysis of existing clinical datasets that the HHLA2 pathway is an important tumor-suppressive mechanism in many patients, NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. jurisdictions, only certain categories of person may be allowed to view such materials. 50
This announcement is an advertisement and does not, under any circumstances, constitute a public
We are currently looking to add an Associate Director or Director, Clinical Operations to our fast moving, roll-up your sleeves team environment. Please note that if you are visiting the Site from outside of the United States, your information may be transferred to, stored, and/or processed in the US. New Talent, Bayer 04
Cookies, as well as other tracking technologies, such as HTML5 local storage, and Local Shared Objects (such as Flash cookies), and similar mechanisms, may record information such as a unique identifier, information you enter in a form, IP address, and other categories of data. Disseminate materials that impact or invade the privacy of others, such as photographs, video clips, sound recordings, personally identifiable information, or other materials that reveal personal, private or sensitive information about another person, without that persons consent. CAMBRIDGE, Mass. Furthermore, where permissible, we may charge for this service. These factors include those discussed in Bayers public reports which are available on the Bayer website at www.bayer.com. | Learn more about Anne Koehler, PhD's . Dr. Zang is professor of microbiology & immunology, of medicine, . To analyze and improve our Services, administer our Site and Services, provide you with access to our Services, analyze and improve our information technology, monitor compliance with our Terms of Use, and enforce our Terms of Use or other legal or regulatory obligations. Detlev is a serial entrepreneur and an experienced biopharma executive who brings deep knowledge of oncology and immuno-oncology to his role. our employees, International
Use, Privacy
Leena Gandhi, MD, PhD, was named chief medical officer of NextPoint Therapeutics, a biotechnology company focused on immuno-oncology through its work on the HHLA2 pathway. Vote, Voting
NextPoint originated from the combined expertise of its academic founders, Gordon Freeman, PhD, of the Dana-Farber Cancer Institute, and XingXing Zang, PhD, of Albert Einstein College of Medicine. You can use the Easy Apply feature on LinkedIn view job description. News, Conditions of
With our distinctive knowledge of people, animals and plants, we focus on the areas of health care and nutrition. NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells Cookies can remember login information, preferences, and similar information. Council, Stakeholder
2+ years experience managing direct reports including oversight of CRAs. Previous study start-up and clinical monitoring experience desired. Oricell Therapeutics was founded in 2015 as an innovative biopharmaceutical company in China. China, United
NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi.. NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. Germany
Copyright and Legal Notice. Leena is a proven leader in immuno-oncology and a brilliant physician-scientist, and our team will benefit greatly from her academic and drug development expertise as NextPoint moves forward in its next stage of growth, said Detlev Biniszkiewicz, PhD, Chief Executive Officer of NextPoint Therapeutics. Cambridge, MA / Leverkusen, Germany, January 10, 2023 NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. Jan 10, 2023. www.precisiononcologynews.com . Postings, Latest
Worldwide, News &
Some cookies and other technologies may serve to track Personal Data previously entered by a web user on our site. any facility of a national securities exchange of the United States and the tender offer cannot be
2021 Feb;9(2):156-169. NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO).. As CMO, Dr. Gandhi will oversee the clinical development of NextPoint's precision immuno-oncology programs that target the newly discovered HHLA2 pathway to activate anti-tumor immune responses. Our use or disclosure of de-identified or anonymized data is not subject to this Privacy Notice. on
& Medical Devices, Crop
to apply, The
Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. About NextPoint Therapeutics. The Bayer brand stands for trust, reliability and quality throughout the world. 2021 Jul 9;6(61):9792. Any person who is not a relevant person should not act or rely on the
14 new chief medical officers in February Clin Cancer Res. Contact Information Website www.nextpointtx.com Ownership Status Privately Held (backing) Financing Status Venture Capital-Backed Primary Industry Drug Discovery Independently design, execute and manage translational research activities from discovery through clinical development, Develop and implement research and clinical-level assays, along with data analysis, interpretation, and report generation, Work closely with the research and preclinical team to identify novel biomarkers and translate to the clinical setting, Integrate biomarker and clinical data to guide patient stratification, Manage CROs responsible for the generation of both exploratory and clinical biomarker data, Contribute to clinical documents such as, INDs, IBs, regulatory submissions, laboratory manuals and clinical protocols, Function as a scientific thought leader inside the company for cutting edge biomarker approaches. This announcement does not contain or constitute an offer of,
Leaps by Bayer and Sanofi Ventures led the round for the Cambridge, Massachusetts-based company. We are thrilled to support NextPoint, an exciting addition to our oncology portfolio, as it works to redefine the treatment landscape of immuno-oncology.. Conduct, Product
Tuesday's. We will also retain your Personal Data as necessary to comply with our legal obligations, resolve disputes, and enforce our agreements. Innovations, Redefining
public offer of the securities in the United States. Leena Gandhi, director of the Dana-Farber Cancer Institute's Center for Cancer Therapeutic Innovation and a 15-year veteran of the organization, has left to become chief medical officer of. While immune checkpoint inhibitors targeting PD-1/L1 have revolutionized cancer treatments,. NextPoint Therapeutics, Inc. Street Address 1 Street Address 2; 238 MAIN STREET: City State/Province/Country ZIP/PostalCode Phone Number of Issuer; CAMBRIDGE: MASSACHUSETTS: 02142: 5082041115: 3. The Site provides a venue to obtain information about NextPoint, our activities, and products we may offer. Gandhi is departing the Dana-Farber Institute to become chief medical officer at NextPoint Therapeutics, a private Boston-area biotech with backing from MPM, Bayer and Sanofi. Prospectus Directive. jurisdiction. Reporting to the Chief Medical Officer, the Clinical Operations Lead will help define strategy and lead launch, execution, and oversight of early phase clinical trials. We also use cookies and similar technologies for purposes of marketing and advertising. One of the candidates, lademirsen, is in a phase 2 trial for the treatment of Alport Syndrome. Results, AGM
NextPoint is building a deep understanding of the HHLA2 tumor-specific immune-escape mechanism, with the ultimate goal of establishing standalone treatments in cancers with high HHLA2 expression, said Detlev Biniszkiewicz, PhD, Chief Executive Officer of NextPoint Therapeutics. Counterfeits, Recognizing
The securities referred to herein will not be registered under the U.S. Securities Act of 1933, as
R&D expenses before special items amounted to 5.3 billion euros.
Contact Us - Nextpoint About NextPoint Therapeutics Founded by MPM Capital, NextPoint Therapeutics, Inc. has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies with the goal of delivering new options to people with cancer. Dialogue, UN Global
NextPoint Therapeutics Appoints Leena Gandhi, MD, PhD, as Chief Medical search, Main
The above described license is conditioned on your compliance with these Terms, and shall terminate upon termination of these Terms. NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO).. As CMO, Dr. Gandhi will oversee the clinical development of NextPoint's precision immuno-oncology programs that target the newly discovered HHLA2 pathway to activate anti-tumor immune responses. KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. NextPoint does not sell your Personal Information. Please note that the Site does not alter its behavior or use practices when we receive a Do Not Track signal from your browser.
Stock Market | Finance As part of the financing, Rakhshita Dhar, Senior Director of Venture Investments Health at Leaps by Bayer, and Paulina Hill, Partner at Sanofi Ventures, will join the NextPoint Board of Directors. Existing investors that took part in the financing include MPM Capital Management, Dana-Farber Cancer Institutes Binney Street Capital and NextPoint founder Gordon Freeman, PhD. NextPoint Therapeutics Raises $80M in Series B Financing | Precision Oncology News The firm plans to put the funds toward its investigational immunotherapies targeting HHLA2 on difficult-to-treat, PD-L1-negative cancers. CAMBRIDGE, Mass. The tender offer referenced herein is not being made, directly or
Phone:
+49 30 468 1111, Alfred-Nobel-Str. The Bayer brand stands for trust, reliability and quality throughout the world. The online community has not agreed on what actions, if any, should be taken by the websites that receive the do not track signal, and therefore Do-Not-Track is not yet standardized. Kong, China, Ireland,
Audio, electronic, visual, thermal, olfactory or similar information, We generally do not collect this type of information, Inferences drawn from other Personal Information. For more information, go to www.bayer.com.
Aktis Oncology Announces $72M Series A Financing To Advance Find out more: This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. announcements and other documents available in electronic format on this webpage does not constitute
Regulations, Sustainable